Lv11
18 积分 2022-06-27 加入
Hepatic Events During Immune Checkpoint Inhibitor Treatment Between Liver and Non‐Liver Malignancies in Hepatitis B Endemic Areas
55分钟前
已完结
Hepatitis associated with immune checkpoint inhibitors-based combinations of other therapies: A real-world pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database
1小时前
已完结
Single-cell transcriptomics unveils the immunologic landscape of anti-PD-1-associated indirect drug-induced liver injury
8小时前
已完结
A proteomics approach to identifying key protein targets involved in VEGF inhibitor mediated attenuation of bleomycin‐induced pulmonary fibrosis
8天前
已完结
Checkpoint Inhibitor Pneumonitis in Non‐Small Cell Lung Cancer With Chronic Lung Disease: A Comparative Study of ILD , COPD , and the General Population Using a Global Federated Database
9天前
已完结
Anti–interleukin‐6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis
17天前
已完结
PD-1 inhibitor causes pathological injury to multiple organs in a Lewis lung cancer mouse model
17天前
已完结
Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review
1个月前
已完结
Precision Immunomodulation: Understanding and Harnessing Cytokine Pathways to Treat and Prevent Immune-Related Adverse Events (irAEs)
1个月前
已完结
Refractory immune-related adverse events (irAEs) associated with immune checkpoint inhibitor therapy: a multiorgan management review
1个月前
已完结
皖公网安备34019202002308
